Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Oct 09, 2021 3:32pm

199 Views

Post# 33992242

Arch Share Structure

The Company had 47,360,179 Common Shares outstanding as of May 7, 2010. As of the date hereinabove, the Company has 61,862,302 common shares outstanding.

Insiders control 58.08 Percent

Muruve, Richard the CEO owns and controls 11,736,700 shares / 18.97 Percent

He also last purchased shares in the $1.40-1.50 range in January 2020.

If the market wants a position in Arch Biopartners, the price point will have to be considerably higher than here.

5% of the companies shares have traded since Aug 5th news

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading